In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment
(2021) Cancers — Vol. 13, n° 3, p. 569 (2021)
Files
120ZohraMCT1tox.pdf
Open Access - Adobe PDF
- 920.45 KB
Details
- Authors
- Affiliations
Citations
Benyahia, Z., Blackman, M., Hamelin, L., Zampieri, L., De Miranda Capeloa, T. I., Bedin, M., Vazeille, T., Schakman, O., & Sonveaux, P. (2021). In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment. Cancers, 13(3), 569. https://doi.org/10.3390/cancers13030569 (Original work published 2021)